Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
32
WST Quote, Financials, Valuation and Earnings
Last price:
$221.65
Seasonality move
:
0.32%
Day range:
$219.46 - $224.73
52-week range:
$187.43 - $352.33
Dividend yield:
0.37%
P/E ratio:
35.22x
P/S ratio:
5.69x
P/B ratio:
6.01x
Volume:
365.7K
Avg. volume:
632.2K
1-year change:
-31.82%
Market cap:
$16.1B
Revenue:
$2.9B
EPS (TTM):
$6.37
Analysts' Opinion
-
Consensus RatingWest Pharmaceutical Services has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $278.84, West Pharmaceutical Services has an estimated upside of 24.27% from its current price of $224.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $245.00 representing 100% downside risk from its current price of $224.38.
Fair Value
-
According to the consensus of 11 analysts, West Pharmaceutical Services has 24.27% upside to fair value with a price target of $278.84 per share.
WST vs. S&P 500
-
Over the past 5 trading days, West Pharmaceutical Services has underperformed the S&P 500 by -0.86% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
West Pharmaceutical Services does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
West Pharmaceutical Services has grown year-over-year revenues for 2 quarters straight. In the most recent quarter West Pharmaceutical Services reported revenues of $698M.
Earnings Growth
-
West Pharmaceutical Services earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter West Pharmaceutical Services reported earnings per share of $1.23.
Enterprise value:
15.9B
EV / Invested capital:
--
Price / LTM sales:
5.69x
EV / EBIT:
27.91x
EV / Revenue:
5.50x
PEG ratio (5yr expected):
18.00x
EV / Free cash flow:
51.87x
Price / Operating cash flow:
53.65x
Enterprise value / EBITDA:
21.80x
Gross Profit (TTM):
$1B
Return On Assets:
12.96%
Net Income Margin (TTM):
16.13%
Return On Equity:
17.47%
Return On Invested Capital:
16.23%
Operating Margin:
18.28%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.9B | $2.9B | $2.9B | $695.4M | $698M | |
| Gross Profit | $1.1B | $1.1B | $1B | $230.2M | $231.9M | |
| Operating Income | $742.4M | $665.1M | $592.6M | $125.9M | $127.6M | |
| EBITDA | $780.5M | $817.2M | $730.2M | $164.6M | $150.9M | |
| Diluted EPS | $7.28 | $7.58 | $6.37 | $1.55 | $1.23 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.3B | $1.7B | $1.9B | $1.7B | $1.5B | |
| Total Assets | $2.7B | $3.3B | $3.7B | $3.6B | $3.6B | |
| Current Liabilities | $482.8M | $584.8M | $534.9M | $648.4M | $526.7M | |
| Total Liabilities | $910.7M | $968.5M | $947.4M | $921.7M | $935.1M | |
| Total Equity | $1.8B | $2.3B | $2.8B | $2.7B | $2.7B | |
| Total Debt | $254.6M | $252.5M | $208.3M | $206.2M | $202.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $710.9M | $756.6M | $664.6M | $118.2M | $129.4M | |
| Cash From Investing | -$302M | -$377.2M | -$359.4M | -$90.6M | -$71.3M | |
| Cash From Financing | -$191.9M | -$659.6M | -$498.6M | -$271M | -$147M | |
| Free Cash Flow | $410M | $386.1M | $306.9M | $27.6M | $58.1M | |
WST
Sector
Market Cap
$16.1B
$34.4M
Price % of 52-Week High
63.69%
48.88%
Dividend Yield
0.37%
0%
Shareholder Yield
3.05%
-1.01%
1-Year Price Total Return
-31.82%
-37.36%
Beta (5-Year)
1.088
0.614
Dividend yield:
0.37%
Annualized payout:
$0.81
Payout ratio:
12.76%
Growth streak:
32 years
Technicals
8-day SMA
Buy
Level
$224.31
200-day SMA
Sell
Level
$267.47
Bollinger Bands (100)
Buy
Level
209.23 - 226.59
Chaikin Money Flow
Buy
Level
182.7K
20-day SMA
Buy
Level
$221.46
Relative Strength Index (RSI14)
Buy
Level
54.54
ADX Line
Buy
Level
23.21
Williams %R
Neutral
Level
-52.0495
50-day SMA
Buy
Level
$217.53
MACD (12, 26)
Buy
Level
61.25
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Sell
Level
-299.4K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (17.9575)
Buy
CA Score
(Annual)
Level (1.6712)
Buy
Beneish M-Score
(Annual)
Level (-2.4354)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-3.2646)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Stock Forecast FAQ
In the current month, WST has received 9 Buy ratings 2 Hold ratings, and 0 Sell ratings. The WST average analyst price target in the past 3 months is $278.84.
-
Where Will West Pharmaceutical Services Stock Be In 1 Year?
According to analysts, the consensus estimate is that West Pharmaceutical Services share price will rise to $278.84 per share over the next 12 months.
-
What Do Analysts Say About West Pharmaceutical Services?
Analysts are divided on their view about West Pharmaceutical Services share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that West Pharmaceutical Services is a Sell and believe this share price will drop from its current level to $245.00.
-
What Is West Pharmaceutical Services's Price Target?
The price target for West Pharmaceutical Services over the next 1-year time period is forecast to be $278.84 according to 11 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is WST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for West Pharmaceutical Services is a Buy. 9 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of WST?
You can purchase shares of West Pharmaceutical Services via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase West Pharmaceutical Services shares.
-
What Is The West Pharmaceutical Services Share Price Today?
West Pharmaceutical Services was last trading at $221.65 per share. This represents the most recent stock quote for West Pharmaceutical Services. Yesterday, West Pharmaceutical Services closed at $224.38 per share.
-
How To Buy West Pharmaceutical Services Stock Online?
In order to purchase West Pharmaceutical Services stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
